Trials / Conditions / Medullary Thyroid Carcinoma

Medullary Thyroid Carcinoma

20 registered clinical trials studyying Medullary Thyroid Carcinoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC NCT07383246	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 3
Recruiting	Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC NCT07138716	Luo Yaping	N/A
Enrolling By Invitation	PET-TC in Thyroid Evaluation NCT06852144	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Not Yet Recruiting	Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications NCT06121271	University College, London	Phase 2
Recruiting	Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma NCT06520319	First Affiliated Hospital of Fujian Medical University	Phase 1
Completed	Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer NCT05534594	University Medical Center Groningen	N/A
Unknown	A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) NCT04787328	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 2
Active Not Recruiting	Spanish Study for Molecular Characterization of Thyroid Carcinoma NCT04970134	Grupo Español de Tratamiento de Tumores de Cabeza y Cuello	—
Unknown	Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma NCT03636945	Assistance Publique Hopitaux De Marseille	N/A
Completed	Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. NCT06067594	Austral University, Argentina	—
Completed	Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC NCT03246659	Paola Anna Erba	Phase 1
Completed	Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) NCT02586350	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2 / Phase 3
Completed	ImmunoTEP for Patients With Medullary Thyroid Carcinoma. NCT01730638	Nantes University Hospital	Phase 1 / Phase 2
Withdrawn	Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma NCT01736878	Eanm Research Ltd	Phase 2
Enrolling By Invitation	An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) NCT01511393	Novo Nordisk A/S	—
Completed	Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Beh NCT01424878	National Cancer Institute (NCI)	—
Terminated	A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade NCT00923247	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer NCT00514046	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Collection of Tissue Samples for Study of Multidrug Resistance NCT00880503	National Cancer Institute (NCI)	—
Unknown	123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors NCT01373736	Vancouver Coastal Health	Phase 3